Journey Medical (DERM) Change in Receivables (2020 - 2026)

Journey Medical has reported Change in Receivables for 7 years, with the latest figure at -$4.8 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables fell 159.59% year-over-year to -$4.8 million; the trailing twelve-month figure through Mar 2026 stood at $6.6 million (down 26.2% YoY), and the FY2025 full-year result was $19.3 million, up 532.2% from the prior year.
• Change in Receivables for Q1 2026 stood at -$4.8 million, down from $11.8 million in the prior quarter.
• The five-year high for Change in Receivables was $11.8 million in Q4 2025, with the low at -$10.4 million in Q2 2023.
• Historically, Change in Receivables has averaged $172588.2 across 5 years, with a median of -$83000.0 in 2022.
• The largest YoY upside for Change in Receivables was 14170.59% in 2023 against a maximum downside of 10538.55% in 2023.
• Journey Medical's Change in Receivables stood at -$51000.0 in 2022, then surged by 14170.59% to $7.2 million in 2023, then sank by 110.41% to -$747000.0 in 2024, then surged by 1674.16% to $11.8 million in 2025, then sank by 140.49% to -$4.8 million in 2026.
• The last three Change in Receivables figures came in at -$4.8 million (Q1 2026), $11.8 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.